Department of Physiology, National University of Singapore.
Clin Exp Allergy. 2011 Dec;41(12):1793-803. doi: 10.1111/j.1365-2222.2011.03855.x. Epub 2011 Sep 20.
Glucocorticoids are the mainstream drugs used in the treatment and control of inflammatory diseases such as asthma. Annexin-1 (ANXA1) is an anti-inflammatory protein which has been described as an endogenous protein responsible for some anti-inflammatory glucocorticoid effects. Previous studies have identified its importance in other immune diseases such as rheumatoid arthritis and cystic fibrosis. ANXA1-deficient ((-/-)) mice are Th2 biased, and ANXA1 N-terminus peptide exhibits anti-inflammatory activity in a rat model of pulmonary inflammation.
ANXA1 protein is found in bronchoalveolar lavage fluid from asthmatics. However, the function of ANXA1 in the pathological development of allergy or asthma is unclear. Thus, in this study we intended to examine the effect of ANXA1 deficiency on allergen-specific antibody responses and airway responses to methacholine (Mch).
ANXA1(-/-) mice were sensitized with ovalbumin (OVA) and challenged with aerosolized OVA. Airway resistance, lung compliance and enhanced pause (PenH) were measured in naïve, sensitized and saline or allergen-challenged wild-type (WT) and ANXA1(-/-) mice. Total and allergen-specific antibodies were measured in the serum.
We show that allergen-specific and total IgE, IgG2a and IgG2b levels were significantly higher in ANXA1(-/-) mice. Furthermore, naïve ANXA1(-/-) mice displayed higher airway hypersensitivity to inhaled Mch, and significant differences were also observed in allergen-sensitized and allergen-challenged ANXA1(-/-) mice compared with WT mice.
In conclusion, ANXA1(-/-) mice possess multiple features characteristic to allergic asthma, such as airway hyperresponsiveness and enhanced antibody responses, suggesting that ANXA1 plays a critical regulatory role in the development of asthma.
We postulate that ANXA1 is an important regulatory factor in the development of allergic disease and dysregulation of its expression can lead to pathological changes which may affect disease progression.
糖皮质激素是治疗和控制哮喘等炎症性疾病的主流药物。膜联蛋白-1(ANXA1)是一种抗炎蛋白,被描述为负责某些抗炎糖皮质激素作用的内源性蛋白。先前的研究已经确定了它在其他免疫性疾病(如类风湿关节炎和囊性纤维化)中的重要性。ANXA1 缺陷((-/-))小鼠呈 Th2 偏向性,并且 ANXA1 N 端肽在大鼠肺炎症模型中具有抗炎活性。
哮喘患者的支气管肺泡灌洗液中发现了 ANXA1 蛋白。然而,ANXA1 在过敏或哮喘的病理发展中的功能尚不清楚。因此,在这项研究中,我们旨在研究 ANXA1 缺乏对过敏原特异性抗体反应和气道对乙酰甲胆碱(Mch)反应的影响。
用卵清蛋白(OVA)致敏 ANXA1(-/-) 小鼠,并通过雾化 OVA 进行挑战。在未致敏、致敏和生理盐水或过敏原攻击的野生型(WT)和 ANXA1(-/-) 小鼠中测量气道阻力、肺顺应性和增强呼气暂停(PenH)。测量血清中的总抗体和过敏原特异性抗体。
我们表明,过敏原特异性和总 IgE、IgG2a 和 IgG2b 水平在 ANXA1(-/-) 小鼠中显著升高。此外,在 ANXA1(-/-) 小鼠中,气道对吸入 Mch 的高敏性明显更高,与 WT 小鼠相比,在致敏和过敏原攻击的 ANXA1(-/-) 小鼠中也观察到显著差异。
总之,ANXA1(-/-) 小鼠具有过敏性哮喘的多种特征,如气道高反应性和增强的抗体反应,表明 ANXA1 在哮喘的发展中起关键调节作用。
我们推测 ANXA1 是过敏性疾病发展中的一个重要调节因子,其表达失调可能导致影响疾病进展的病理变化。